Selected Treatment Schedules: Adenocarcinoma, Pancreas

Selected Treatment Schedules

2dd, twice daily; AUC, area under the concentration–time curve; BMI, body mass index; FU, fluorouracil; HER2, human Epidermal growth factor receptor 2; FOLFIRI, folinic acid, fluorouracil and irinotecan; 5-FU, 5-fluorouracil.

Adenocarcinoma, Pancreas

(Neo)adjuvant Palliative
4-weekly gemcitabine 1000 mg/m2 d1, 8, 15[25] 4-weekly gemcitabine 1000 mg/m2, nab-paclitaxel 125 mg/m2 d1, 8, 15[26]
--- FOLFIRINOX: oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, 5-FU 2400 mg/m2/46 h[27]

References

25. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310:1473–1481.

26. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691–1703.

27. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817–1825.

Last update: 08 July 2016